Predictive Value of Plasma Biomarkers in Tau-PET Transitions

10 September, 2025

Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images

4 September, 2025

Association of plasma Alzheimer’s disease biomarkers with cognitive decline in cognitively unimpaired individuals

2 September, 2025

Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease

25 August, 2025

Olfactory dysfunction and amyloid-positivity in Parkinson’s disease-longitudinal analysis of cognitive decline and cerebrospinal fluid markers

21 August, 2025

Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease

14 August, 2025

Modernizing diagnosis of Alzheimer’s disease: A review of global trends and Asia-specific perspectives

4 August, 2025

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease

Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings

25 July, 2025

Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer’s disease

21 July, 2025

Long-term exposure to air pollution and validated cases of Alzheimer’s disease and vascular dementia in the Malmö diet and cancer cohort.

Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

20 July, 2025

Personalised regional modelling predicts tau progression in the human brain

Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer’s disease and non-AD dementias: An international multi-center study

19 July, 2025

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

16 July, 2025

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity

15 July, 2025

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases.

Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer’s disease

13 July, 2025

Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease

1 July, 2025

Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,170 people

27 June, 2025

Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants

23 June, 2025

Development and validation of a novel Simoa assay for NPTX2 in Alzheimer’s disease and Down syndrome

12 June, 2025

Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer’s disease: A consecutive mixed memory clinic cohort study

11 June, 2025

Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging: TAU-SPEX

7 June, 2025

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

30 May, 2025

Age and Alzheimer’s disease affect functional connectivity along separate axes of functional brain organization

22 May, 2025

Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration

16 May, 2025

Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab

30 April, 2025

Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Are Elevated in Bipolar Depression: Evidence for Neuroprogression and Astrogliosis

23 April, 2025

The CentiMarker project: Standardizing quantitative Alzheimer’s disease fluid biomarkers for biologic interpretation.

15 April, 2025

Characterizing visual read tau-PET-negative participants with Alzheimer’s disease dementia

Associations between the EAT-Lancet planetary health diet and incident dementia.

12 April, 2025

A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease.

31 March, 2025

The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus.

20 March, 2025

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer’s disease.

15 March, 2025

Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer’s disease assessment: findings from the Apollo study

13 March, 2025

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.

3 March, 2025

Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice.

2 March, 2025

Biofluid biomarkers in distinguishing young-onset dementia from primary psychiatric disorders

1 March, 2025

The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.

5 February, 2025

Toward a biological definition of neuronal and glial synucleinopathies.

1 February, 2025

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

29 January, 2025

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum.

Blood Biomarkers to Detect Alzheimer Disease-Reply.

Expert opinions on pharmacological symptomatic treatment of behavioral symptoms in frontotemporal dementia: A survey of the Neuropsychiatric International Consortium on Frontotemporal Dementia (NIC-FTD)

16 January, 2025

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta.

Cutting through the noise: A narrative review of Alzheimer’s disease plasma biomarkers for routine clinical use

14 January, 2025

Point of view: Challenges in implementation of new immunotherapies for Alzheimer’s disease

10 January, 2025

Amyloid-β and tau deposition in traumatic brain injury: a study of Vietnam War veterans

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease.

8 January, 2025

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia.

6 January, 2025

Benchmarking Alzheimer’s disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies.

Diffusion tensor imaging along the perivascular space: the bias from crossing fibres.

5 January, 2025

Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.

17 December, 2024

Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison.

16 December, 2024

Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.

15 December, 2024

Balance and gait disorders in de novo Parkinson’s disease: support for early rehabilitation.

12 December, 2024

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.

Altered Empathy Processing in Frontotemporal Dementia.

2 December, 2024

Multiomics profiling of DNA methylation, microRNA, and mRNA in skeletal muscle from monozygotic twin pairs discordant for type 2 diabetes identifies dysregulated genes controlling metabolism.

Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.

19 November, 2024

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.

15 November, 2024

Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.

12 November, 2024

GBA1 T369M and Parkinson’s disease – Further evidence of a lack of association in the Swedish population.

31 October, 2024

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.

28 October, 2024

Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.

25 October, 2024

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.

12 October, 2024

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease.

11 October, 2024

Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease

10 October, 2024

Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.

6 October, 2024

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.

1 October, 2024

Dementia in Down syndrome

30 September, 2024

Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome.

25 September, 2024

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease.

Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions.

19 September, 2024

Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer’s disease

17 September, 2024

Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease.

16 September, 2024

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.

14 September, 2024

Associations between misfolded alpha-synuclein aggregates and Alzheimer’s disease pathology in vivo.

11 September, 2024

Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies.

26 August, 2024

The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.

22 August, 2024

Disentangling genetic risks for development and progression of Alzheimer’s disease.

1 August, 2024

The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation

29 July, 2024

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

28 July, 2024

Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population

Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model

23 July, 2024

A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease

20 July, 2024

Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study

10 July, 2024

Divergent functional connectivity changes associated with white matter hyperintensities

Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity

9 July, 2024

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

6 July, 2024

A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

5 July, 2024

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests

Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns

Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease

1 July, 2024

Revised criteria for the diagnosis and staging of Alzheimer’s disease

28 June, 2024

Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup

27 June, 2024

Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals

26 June, 2024

Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers

22 June, 2024

In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives

21 June, 2024

Structural and functional connectivity associations with anterior cingulate sulcal variability

20 June, 2024

Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study

18 June, 2024

MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults

15 June, 2024

Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology

13 June, 2024

Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer’s disease

12 June, 2024

Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

10 June, 2024

Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling

A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variables

31 May, 2024

Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

23 May, 2024

Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease

21 May, 2024

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

12 May, 2024

Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison

3 May, 2024

Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease

1 May, 2024

Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

20 April, 2024

Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest

9 April, 2024

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia

8 April, 2024

Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.

28 March, 2024

Altered empathy processing in frontotemporal dementia A task-based fMRI study

26 March, 2024

Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms

19 March, 2024

Is GBA1 T369M not a risk factor for Parkinson’s disease in the Swedish population?

16 March, 2024

A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

14 March, 2024

Prognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review.

16 February, 2024

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.

14 September, 2023

Cognitive effects of Lewy body pathology in clinically unimpaired individuals.

Clinical effects of Lewy body pathology in cognitively impaired individuals.

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.

Direct Conversion of Fibroblast into Neurons for Alzheimer’s Disease Research: A Systematic Review

25 August, 2023

The emerging era of staging Alzheimer’s disease pathology using plasma biomarkers

2 May, 2023

Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest

24 February, 2023